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with ESRD caused by lupus nephritis and patients with ESRDOutcomes of renal transplantation among patients with end-
from other causes.stage renal disease caused by lupus nephritis.
Background. Although the outcomes of renal transplanta-
tion among patients with end-stage renal disease (ESRD)
caused by lupus nephritis have generally been found to be
Renal transplantation among patients with end-stagecomparable to those of patients with other causes of ESRD,
renal disease (ESRD) caused by lupus nephritis becamesome studies indicate that cadaveric graft failure is more com-
mon among these patients. However, most previous studies an established practice after reports that early graft sur-
examined small numbers of patients and did not adjust for vival in these patients was comparable to that of patients
important confounding factors. with other causes of ESRD [1]. Many subsequent studies
Methods. Graft failure and patient mortality after the first
have supported these findings [2–18]. However, mostcadaveric renal transplantation were compared between 772
have been single-center studies that examined smalladults with ESRD caused by lupus nephritis and 32,644 adults
with ESRD caused by other causes who received a transplant numbers of patients. Many studies used historical con-
between 1987 and 1994 and were included in the United States trols and did not formally compare outcomes with those
Renal Data System. The median follow-up times were 4.9 and of transplant patients with other causes of ESRD who5.0 years in the two groups, respectively. Multivariate Cox
were followed concurrently. In larger multicenter studiesregression models were used to adjust the risks of graft failure
and reports based on registry data, cadaveric graft sur-and mortality for group differences in recipient and donor
characteristics. Similar comparisons were performed between vival often tended to be lower among patients with ESRD
390 adults with ESRD caused by lupus nephritis and 10,512 caused by lupus nephritis [19–23]. In some studies, cadav-
adults with ESRD caused by other causes after first living- eric graft survival was significantly lower among theserelated renal transplantation.
patients [24–29].Results. In an unadjusted analysis, the risk of graft failure
Assessment of the outcomes of renal transplantationafter first cadaveric transplant was slightly but significantly
greater among patients with ESRD caused by lupus nephritis in patients with ESRD caused by lupus nephritis is also
than among those with ESRD caused by other causes [hazard limited because few studies that compare the risk of graft
ratio (HR), 1.13; 95% CI, 1.01 to 1.26, P 5 0.04]. However,
failure between transplant patients with and without ESRDafter adjustment for potential confounding factors, the risk of
caused by lupus nephritis adjust these comparisons forgraft failure was not increased in patients with ESRD caused
by lupus nephritis (HR, 1.08; 95% CI, 0.94 to 1.23, P 5 0.28). differences in potential confounding factors [5, 10, 16,
Mortality after the first cadaveric transplantation did not differ 18, 25, 29]. Because transplant patients with ESRD
between groups. The adjusted risks of graft failure (HR, 1.06; caused by lupus nephritis tend to be younger than trans-95% CI, 0.84 to 1.32, P 5 0.62) and patient mortality (HR 5
plant patients with ESRD from other causes and because0.69; 95% CI, 0.45 to 1.05, P 5 0.09) after the first living-related
graft survival is higher among younger recipients, differ-renal transplant were also not significantly higher among pa-
tients with ESRD caused by lupus nephritis. ences in graft survival attributed to the primary renal
Conclusions. Graft and patient survival after first cadaveric disease may merely reflect differences in the ages of the
and first living-related renal transplants are similar in patients
groups. Recipient sex, race, and other factors may have
similar or countervailing influences on estimates of rela-
tive graft survival.Key words: lupus nephritis, renal transplantation, end-stage renal dis-
ease, USRDS. In this study, data from the United States Renal Data
System (USRDS) were used to compare the risks of
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and patients with ESRD caused by other causes. Multi- normal distributions, and chi-square tests for categorical
variables. All hypotheses were two tailed.variate statistical methods were used to adjust these risks
for potentially important confounding factors. Survival analysis was used to compare the probabilities
of graft failure and patient mortality between patients
with ESRD caused by lupus nephritis and patients with
METHODS ESRD due to other causes. The starting date for these
Data analyses was the date of transplantation. In the analysis
of graft survival, both graft failure and death were consid-The USRDS has collected information on all patients
ered events of interest, and patients with functioningin the United States who have received Medicare-reim-
grafts were censored on July 31, 1997. Separate analysesbursed maintenance renal replacement therapy since
that treated patients who died with a functioning graft1977 [30]. The database is estimated to include approxi-
as censored observations yielded almost identical resultsmately 94% of patients who receive renal replacement
and are not reported. In the analysis of mortality, pa-therapy in the United States. To be included in the data-
tients who had not died were censored on July 31, 1997.base, patients must be receiving chronic dialysis or have
Kaplan–Meier survival probabilities between groupshad a renal transplant.
were compared using the log-rank test.The database includes information on patient demo-
Cox regression models were used to compute risk esti-graphic characteristics, the type and timing of different
mates for graft failure and patient mortality that weremodes of renal replacement therapy (including trans-
adjusted for potential confounding factors [31]. In theplantation and graft failure), and mortality. Diagnoses
analysis of cadaveric transplants, these factors includedof the primary renal disease causing ESRD, including
recipient age, sex, race (white, black, Asian, or other),lupus nephritis, were based on clinical attributions of
year of transplantation, number of human leukocyte an-the treating nephrologist and not necessarily based on
tigen (HLA)-A, HLA-B, and HLA-DR mismatches, do-histologic evidence. Since 1987, a single protocol has
nor age (categorized as 0 to 12 years, 13 to 29 years, 30been used to identify the occurrence of renal transplanta-
to 49 years, and $50 years), donor sex, donor race, lengthtion, with the United Network for Organ Sharing being
of cold ischemia time (categorized as ,12 h, 12 to 24 h,the primary source and the Health Care Financing Ad-
and .24 h), and number of preoperative blood transfu-ministration and the Medical Evidence Report forms
sions (categorized as 0, 1 to 5, and .5). All of thesesubmitted by the supervising nephrologist as secondary
factors except donor race and cold ischemia time weresources [30].
also included as potential confounders in the analysesThis study included patients in the USRDS database
of living-related transplants. Donor race was excludedwho began treatment for ESRD on or after January 1,
because it is collinear with recipient race, and cold ische-1987, and who received a renal transplant between Janu-
mia time is less relevant for living-related transplants.ary 1, 1987, and December 31, 1994. Because the out-
Data on recipient age, sex, race, the year of trans-comes of transplantation may differ between children
plantation, HLA mismatches, and donor race were avail-and adults, the study was restricted to those who were
able for all patients, but data on the other variables were18 years old or older when they began treatment for
incomplete. Among patients with cadaveric transplants,ESRD. During the study period, 49,473 renal transplants
data on donor age were missing for 3258 patients (9.7%).were recorded in 45,451 patients. The study was further
Data on donor sex were missing for 1500 patients (4.5%).restricted to first cadaveric or first living-related trans-
Data on cold ischemia time were missing for 5966 pa-plants because too few patients with ESRD caused by
tients (17.8%), and data on the number of transfusionslupus nephritis had second or subsequent transplants for
were missing for 6979 patients (20.9%). The proportionsmeaningful analysis. Patients with cadaveric transplants
of patients with missing data did not differ between those(772 with ESRD caused by lupus nephritis and 32,644
with ESRD caused by other causes) and living-related with ESRD caused by lupus nephritis and those with
transplants (390 with ESRD caused by lupus nephritis other causes of ESRD. Complete data for all variables
and 10,512 caused by other causes) were analyzed sepa- were available for 565 patients with ESRD caused by
rately. Follow-up information on the occurrence of graft lupus nephritis (73%) and 23,439 patients with ESRD
failure or death was available through July 31, 1997. caused by other causes (72%). Among patients with liv-
ing-related transplants, data on donor age were missing
Statistical analysis for 886 patients (8.1%). Data on donor sex were missing
for 519 patients (4.8%), and data on the number of trans-A comparison of demographic and clinical characteris-
tics between patient groups was performed using t-tests fusions were missing for 2362 patients (21.7%). Com-
plete data were available for 320 patients with ESRDfor continuous variables with normal distributions, Wil-
coxon rank-sum tests for continuous variables with non- caused by lupus nephritis (82%) and 8112 patients with
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Table 2. Kaplan-Meier estimates of graft and patient survival afterTable 1. Characteristics of patients with end-stage renal disease due
to lupus nephritis and patients with end-stage renal disease of first cadaveric transplantation in patients with end-stage renal
disease due to lupus nephritis and patients with end-stage renalother causes who received a first cadaveric renal transplant
disease of other causes
Lupus nephritis Other causes
(N 5 772) (N 5 32,644) P Lupus nephritis Other causes P
Age, years (mean6SD) 36.1610.3 43.9612.3 ,0.0001 Graft survival
Female, N (%) 626 (81.1) 12,097 (37.1) ,0.0001 One year 79.1% (76.2–82.1) 83.0% (82.5–83.4) 0.04
Race Three years 67.0% (63.6–70.3) 72.1% (71.6–72.6)
White, N (%) 441 (57.1) 23,960 (73.4) ,0.0001 Five years 58.1% (54.3–61.7) 61.9% (61.3–62.5)
Black, N (%) 279 (36.1) 7,032 (21.5) Patient survival
Asian, N (%) 44 (5.7) 1,035 (3.2) One year 94.4% (92.8–96.0) 93.5% (93.2–93.8) 0.0002
Other, N (%) 8 (1.0) 617 (1.9) Three years 89.6% (87.4–91.7) 86.9% (86.5–87.3)
Donor age Five years 83.8% (81.0–86.5) 78.9% (78.4–79.4)
,13 years, N (%) 75 (9.7) 2,436 (7.5) 0.60
Values in parentheses are 95% confidence intervals. P values are those associ-13–29 years, N (%) 271 (35.1) 12,322 (37.7)
ated with log-rank tests comparing the survival curves.30–49 years, N (%) 224 (29.0) 9,696 (29.7)
$50 years, N (%) 121 (15.7) 5,013 (15.4)
Missing data, N (%) 81 (10.5) 3,177 (9.7)
Donor sex
Male, N (%) 452 (58.5) 19,456 (59.6) 0.62 ESRD caused by other causes (77%) who had living-
Female, N (%) 283 (36.6) 11,725 (35.9)
related transplants.Missing data, N (%) 37 (4.8) 1,463 (4.5)
Donor race Three different strategies were used to accommodate
White, N (%) 570 (73.8) 25,115 (76.9) 0.08 missing data in the multivariate analysis. First, analyses
Black, N (%) 72 (9.3) 2,671 (8.2)
were performed that included only patients with com-Asian, N (%) 17 (2.2) 401 (1.2)
Other, N (%) 113 (14.6) 4,457 (13.7) plete data. Second, analyses were performed using all
Year of transplant patients, with missing values for any variable coded as1987, N (%) 19 (2.5) 988 (3.0) 0.12
separate variables. Third, analyses were performed using1988, N (%) 49 (6.4) 2,701 (8.3)
1989, N (%) 85 (11.0) 3,818 (11.7) all patients, with values imputed for missing data to bias
1990, N (%) 101 (13.1) 4,746 (14.5) results intentionally against patients with ESRD caused1991, N (%) 113 (14.6) 5,114 (15.7)
by lupus nephritis. In this analysis, for example, all re-1992, N (%) 138 (17.9) 5,332 (16.3)
1993, N (%) 160 (20.7) 5,870 (18.0) corded data on donor age were used, but those patients
1994, N (%) 107 (13.9) 4,075 (12.5)
with ESRD caused by lupus nephritis who had missingHLA-A mismatches
None, N (%) 227 (29.4) 8,566 (26.2) 0.13 information on donor age were assigned a donor age
One, N (%) 272 (35.2) 12,287 (37.6) of $ 50 years, while those patients with ESRD caused
Two, N (%) 273 (35.4) 11,791 (36.1)
by other causes who had missing information on donorHLA-B mismatches
None, N (%) 216 (28.0) 7,672 (23.5) 0.009 age were assigned a donor age of 20 to 39 years. This
One, N (%) 252 (32.6) 11,878 (36.4) latter approach provides a sensitivity analysis of the rela-Two, N (%) 304 (39.4) 13,094 (40.1)
tive risks of graft failure and mortality among patientsHLA-DR mismatches
None, N (%) 255 (33.0) 10,119 (31.0) 0.45 with ESRD caused by lupus nephritis under the most
One, N (%) 311 (40.3) 13,738 (42.1) extreme, if improbable, circumstances.Two, N (%) 206 (26.7) 8,787 (26.9)
Cold ischemia time
,12 hours, N (%) 99 (12.8) 5,513 (16.9) 0.003
12–24 hours, N (%) 290 (37.6) 11,972 (36.7) RESULTS
.24 hours, N (%) 243 (31.5) 9,333 (28.6)
Outcomes of cadaveric transplantationsMissing data, N (%) 140 (18.1) 5,826 (17.9)
Number of blood Seven hundred seventy-two patients with ESRD
transfusions
caused by lupus nephritis received a first cadaveric trans-None, N (%) 285 (36.9) 13,564 (41.5) ,0.001
1–5, N (%) 231 (29.9) 9,382 (28.7) plant during the study period, as did 32,644 patients with
.5, N (%) 101 (13.1) 2,874 (8.8) ESRD due to other causes. Those with ESRD causedMissing data, N (%) 155 (20.1) 6,824 (20.9)
by lupus nephritis were younger, more likely to beDuration of dialysis
before transplanta- women, and more likely black or Asian than patients in
tion, days (median) 632.5 467 ,0.0001 the comparison group (Table 1). They were also lessTreatment at hospital
likely to have mismatches for HLA-B antigens, haddischarge
Prednisone, N/N 602/633 26,266/27,767 longer cold ischemia times, had more preoperative blood
observed (%) (95.1) (94.6) 0.85
transfusions, and had received dialysis for a longer timeCyclosporine, N/N 584/626 26,147/27,539
observed (%) (93.3) (95.0) 0.07 than patients with ESRD caused by other causes. Initial
Azathioprine, N/N 549/627 24,508/27,423 immunosuppressive treatments were similar, although
observed (%) (87.6) (89.4) 0.35
data on these treatments were missing for up to 30% ofAntithymocyte
globulin, N/N 135/573 6,677/25,201 patients. The median follow-up times were 4.9 years for
observed (%) (23.6) (26.5) 0.29 patients with ESRD caused by lupus nephritis and 5.0
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Table 3. Relative hazards of graft loss and patient mortality after first cadaveric transplantation among patients with end-stage renal disease
due to lupus nephritis, compared to patients with end-stage renal disease of other causes
Graft loss Patient mortality
Hazard ratio P Hazard ratio P
Unadjusted model 1.13 (1.01–1.26) 0.04 0.73 (0.61–0.86) 0.0002
Multivariate model using only patients with complete data 1.08 (0.94–1.23) 0.28 0.96 (0.78–1.18) 0.72
Multivariate model coding missing values as separate variables 1.12 (0.99–1.25) 0.06 1.00 (0.84–1.19) 0.98
Multivariate model with imputed values for missing values 1.07 (0.96–1.20) 0.21 1.01 (0.85–1.20) 0.89
Values in parentheses are 95% confidence intervals.
years for patients in the comparison group. Three hun- counted for the apparent difference in survival in the
unadjusted analysis.dred thirty-five patients (43.4%) with ESRD caused
by lupus nephritis experienced graft failure, and 140
Outcomes of living-related transplantations(18.1%) died during the follow-up period, as did 41.3%
and 24.9% of patients with ESRD of other causes, re- Three hundred ninety patients with ESRD caused by
spectively. Recurrence of the original disease was noted lupus nephritis had a living-related transplant as their
to be the cause of graft failure in 2 of 127 (1.6%) patients first renal transplant during the study period, as did
with lupus nephritis for whom information on the reason 10,512 patients with ESRD due to other causes. Patients
for graft failure was recorded and in 57 of 4091 (1.4%) with ESRD caused by lupus nephritis undergoing living-
patients with other primary renal diseases for whom in- related transplantation were younger, more likely to be
formation on the reason for graft failure was recorded. women, and more likely black or Asian than patients in
The one-, three-, and five-year graft survival probabili- the comparison group, and also had more preoperative
ties (Kaplan–Meier estimates) among patients with blood transfusions, longer durations of dialysis before
ESRD caused by lupus nephritis were 79.1, 67.0, and transplantation, and were treated with cyclosporine
58.1%, respectively, slightly but significantly lower than slightly more commonly than patients with ESRD caused
that of patients with ESRD caused by other causes (P 5 by other causes (Table 4). The median follow-up times
0.04; Table 2). The unadjusted risk of graft failure was were 5.3 years for patients with ESRD caused by lupus
1.13 times greater among patients with ESRD caused by nephritis and 5.4 years for patients in the comparison
lupus nephritis than among patients in the comparison group. One hundred nine patients (28.0%) with ESRD
group (95% CI, 1.01 to 1.26, P 5 0.04; Table 3). However, caused by lupus nephritis experienced graft failure, and
after adjustment for potential confounding variables, the 34 (8.7%) died during follow-up compared with 26.7%
risk of graft failure was no longer significantly higher and 13.9% of patients with ESRD of other causes, re-
among patients with ESRD caused by lupus nephritis. spectively. Graft failure was attributed to recurrence of
The different methods of treating missing data yielded the original disease in none of the 31 patients with lupus
similar results. nephritis on whom information on the reasons for graft
Among patients with ESRD caused by lupus nephritis, failure was noted and in 25 of 704 patients (3.6%) with
the risk of graft failure decreased by 2% with each year other primary renal diseases on whom information on
of age [adjusted hazard ratio (HR) 5 0.98; 95% CI, 0.97 the reasons for graft failure was recorded.
The one-, three-, and five-year graft survival probabili-to 0.99, P 5 0.02], was 58% higher among blacks than
whites (adjusted HR 5 1.58; 95% CI, 1.18 to 2.10, P 5 ties (Kaplan–Meier estimates) among patients with
ESRD caused by lupus nephritis were 93.6, 84.0, and0.002) and was 53% higher among those whose donor
was age 50 or more compared with those whose donor 77.0%, respectively (Table 5). These estimates were not
significantly different from those of patients with ESRDwas age 13 to 29 (adjusted HR 5 1.53; 95% CI, 1.05 to
2.24, P 5 0.03). No other variables were significantly caused by other causes (P 5 0.35). The unadjusted risk
of graft failure was 1.10 times greater among patientsassociated with graft failure in this group. There was
no association between the duration of dialysis before with ESRD caused by lupus nephritis than among pa-
tients in the comparison group, but this risk was nottransplantation and the risk of graft failure (P 5 0.62).
In the unadjusted analysis, patient survival was sig- significantly elevated (Table 6). Adjustment for potential
confounding variables did not alter this risk estimatenificantly higher among those with ESRD caused by
lupus nephritis (Tables 2 and 3), but there was no differ- substantially.
Among patients with ESRD caused by lupus nephritisence in the risk of patient mortality after first cadaveric
transplantation in the adjusted analyses. Differences be- who received a living-related transplant, the risk of graft
failure decreased by 3% with each year of age (adjustedtween the groups in recipient age and sex largely ac-
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Table 5. Kaplan-Meier estimates of graft and patient survival afterTable 4. Characteristics of patients with end-stage renal disease due
to lupus nephritis and patients with end-stage renal disease of first living-related transplantation in patients with end-stage renal
disease due to lupus nephritis and patients with end-stage renalother causes who received a first living-related renal transplant
disease of other causes
Lupus nephritis Other causes
(N 5 390) (N 5 10,512) P Lupus nephritis Other causes P
Graft survivalAge, years (mean6SD) 32.669.1 38.1612.0 ,0.0001
Female, N (%) 311 (79.7) 4,198 (39.9) ,0.0001 One year 93.6% (91.1–96.0) 91.4% (90.9–92.0) 0.35
Three years 84.0% (80.4–87.7) 84.4% (83.7–85.1)Race
White, N (%) 285 (73.1) 8,691 (82.7) ,0.0001 Five years 77.0% (72.5–81.4) 76.9% (76.0–77.8)
Patient survivalBlack, N (%) 81 (20.8) 1,351 (12.9)
Asian, N (%) 14 (3.6) 246 (2.3) One year 99.2% (98.3–100.0) 97.1% (96.8–97.4) 0.007
Three years 97.2% (95.5–98.8) 93.3% (92.7–93.7)Other, N (%) 10 (2.5) 224 (2.1)
Donor age Five years 94.4% (92.0–96.8) 89.0% (88.3–89.6)
,13 years, N (%) 4 (1.0) 35 (0.3) 0.73 Values in parentheses are 95% confidence intervals. P values are those associ-
13–29 years, N (%) 112 (28.7) 2,575 (24.5) ated with log-rank tests comparing the survival curves.
30–49 years, N (%) 187 (48.0) 5,451 (51.9)
$50 years, N (%) 56 (14.3) 1,596 (15.2)
Missing data, N (%) 31 (8.0) 855 (8.1)
Donor sex
Male, N (%) 175 (44.8) 4,442 (42.2) 0.57 HR 5 0.97; 95% CI, 0.94 to 0.99, P 5 0.02), was 72%
Female, N (%) 196 (50.3) 5,570 (53.0) higher among blacks than whites (adjusted HR 5 1.72;Missing data, N (%) 19 (4.9) 500 (4.8)
95% CI, 1.05 to 2.81, P 5 0.03), and was 83% higherYear of transplant
1987, N (%) 15 (3.8) 563 (5.4) 0.01 among those with one mismatch for HLA-DR antigens
1988, N (%) 24 (6.2) 1,018 (9.7) compared with those with no mismatches (adjusted HR 51989, N (%) 36 (9.2) 1,191 (11.3)
1.83; 95% CI, 1.07 to 3.11, P 5 0.03). No other variables1990, N (%) 59 (15.1) 1,334 (12.7)
1991, N (%) 60 (15.4) 1,564 (14.9) were associated with graft failure in this group, including
1992, N (%) 56 (14.4) 1,737 (16.5) the duration of dialysis before transplantation (P 5 0.64).1993, N (%) 91 (23.3) 1,826 (17.4)
Patient survival after living-related transplantation1994, N (%) 49 (12.6) 1,279 (12.2)
HLA-A mismatches was higher among patients with ESRD caused by lupus
None, N (%) 175 (44.9) 4,839 (46.0) 0.56 nephritis in the univariate analysis (Tables 5 and 6).One, N (%) 188 (48.2) 4,823 (45.9)
However, the risks of mortality were not significantlyTwo, N (%) 27 (6.9) 850 (8.1)
HLA-B mismatches different in the two groups in the multivariate analyses,
None, N (%) 162 (41.5) 4,087 (38.9) 0.49 largely because of adjustment for group differences inOne, N (%) 190 (48.7) 5,259 (50.0)
recipient age.Two, N (%) 38 (9.7) 1,166 (11.1)
HLA-DR mismatches
None, N (%) 184 (47.2) 4,859 (46.2) 0.46
One, N (%) 163 (41.8) 4,659 (44.3) DISCUSSION
Two, N (%) 43 (11.0) 994 (9.5)
This study of a large national sample indicates thatNumber of blood
transfusions graft and patient survival after first cadaveric and first
None, N (%) 155 (39.7) 4,594 (43.7) ,0.0001 living-related renal transplantation are similar in patients1–5, N (%) 118 (30.2) 2,925 (27.8)
with ESRD due to lupus nephritis and patients with.5, N (%) 54 (13.8) 694 (6.6)
Missing data, N (%) 63 (16.2) 2,299 (21.9) ESRD of other causes. Although the unadjusted analysis
Duration of dialysis be- showed a higher rate of cadaveric graft failure amongfore transplantation,
patients with ESRD caused by lupus nephritis, this differ-days (median) 295.5 189 ,0.0001
Treatment at hospital ence was not found after an adjustment for several im-
discharge portant confounding factors. Similarly, although unad-Prednisone, N/N 309/328 8,354/8,865
justed analyses demonstrated lower mortality amongobserved (%) (94.2) (94.2) 0.99
Cyclosporine, N/N 308/326 7,915/8,754 patients with ESRD due to lupus nephritis after either
observed (%) (94.5) (90.4) 0.05 cadaveric or living-related transplantation, these differ-Azathioprine, N/N 274/324 7,646/8,776
ences were not present after an adjustment for differ-observed (%) (84.6) (87.1) 0.40
Antithymocyte ences in recipient age and other confounders.
globulin, N/N 36/303 1,211/7,996 Six previous studies of transplantation outcomes inobserved (%) (11.9) (15.2) 0.29
patients with ESRD caused by lupus nephritis included
both a concurrent comparison group and adjusted for
between-group differences in potential confounding fac-
tors. These studies had varied results, possibly because of
differences in donor source, type of immunosuppression,
and composition of the comparison group. Bumgardner
et al reported living-related graft survival among patients
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Table 6. Relative hazards of graft loss and patient mortality after first living-related transplantation among patients with end-stage renal
disease due to lupus nephritis, compared with patients with end-stage renal disease of other causes
Graft loss Patient mortality
Hazard ratio P Hazard ratio P
Unadjusted model 1.10 (0.90–1.33) 0.35 0.62 (0.44–0.88) 0.008
Multivariate model using only patients with complete data 1.06 (0.84–1.32) 0.62 0.69 (0.45–1.05) 0.09
Multivariate model coding missing values as separate variables 1.09 (0.89–1.32) 0.42 0.78 (0.55–1.11) 0.18
Multivariate model with imputed values for missing values 1.07 (0.88–1.31) 0.49 0.79 (0.56–1.12) 0.19
Values in parentheses are 95% confidence intervals.
with ESRD caused by lupus nephritis to be comparable important to adjust for potential confounding factors so
that differences in outcomes between patient groups canto that of the comparison group, but cadaveric graft
survival at one year was 60% among patients with ESRD be appropriately attributed to the cause of ESRD rather
than other patient characteristics. In this study, data werecaused by lupus nephritis (N 5 10) and 90% among
patients in the comparison group (N 5 20) [5]. Among available to allow control of confounding by recipient
age, sex, and race, donor age and sex, year of transplanta-cyclosporine-treated patients, Krishnan et al reported
that cadaveric graft failure was 34% more likely among tion, the number of HLA mismatches, the number of
preoperative blood transfusions, and for cadaveric trans-138 patients with ESRD caused by lupus nephritis than
among a comparison group [10]. This difference in graft plants, donor race and the length of cold ischemia time.
These factors comprise many of the main determinantssurvival, although sizable, was not significantly differ-
ent, likely because of the low statistical power. Stone, of graft survival [32–38]. However, data were not avail-
able on other potentially important factors that couldAmend, and Criswell found graft failure to be twice
as likely among patients with ESRD caused by lupus influence the comparison of outcomes between patients
with and without ESRD caused by lupus nephritis, suchnephritis in a controlled study of 97 cyclosporine-treated
patients [29]. Nyberg et al reported high rates of early as the level of panel reactive antibodies, size mismatch,
the cause of death of the donor, and the transplantationgraft loss in patients with ESRD caused by lupus nephri-
tis, but long-term graft survival was similar between pa- center [32, 33]. Because high levels of panel reactive
antibodies have been associated with graft failure [32,tients with and without ESRD caused by lupus nephritis
treated with cyclosporine [25]. Graft survival in patients 33, 38] and because patients with ESRD caused by lupus
nephritis commonly have high levels of panel reactivewith and without ESRD caused by lupus nephritis was
also comparable in two additional studies [16, 18]. These antibodies [16, 23], analyses such as ours that do not
adjust for differences in levels of panel reactive antibod-last four studies did not analyze cadaveric and living-
related transplants separately. This distinction is impor- ies may overestimate the risk of graft failure attributed
to ESRD caused by lupus nephritis. Conversely, sizetant because there has been little indication that out-
comes after living-related transplantation are inferior in mismatch may adversely affect graft survival in patients
with ESRD of other causes to a greater extent, becausepatients with ESRD caused by lupus nephritis [21–23,
28]. The heterogeneity of these studies has made it diffi- the majority of graft recipients with ESRD caused by
lupus nephritis were women. It is unlikely that the causecult to draw firm conclusions about the relative risks
of graft failure in patients with ESRD caused by lupus of death of the donor or the transplant center were im-
portant confounders because the cause of ESRD in thenephritis.
Studies since 1981 have all reported low rates of mor- graft recipient is unlikely to vary with these factors. Dif-
ferences between the groups in treatment, compliance,tality after renal transplantation among patients with
ESRD caused by lupus nephritis, with survival at five hypertension, and smoking may have occurred and in-
fluenced their relative outcomes. Information on theyears often greater than 90% [2–6, 8, 9, 11–13, 15–19,
21, 22, 24–27, 29]. None of the controlled studies reported causes of graft failure was missing for more than 70%
of patients, and the database did not include informationdifferences in patient survival between those with and
without ESRD caused by lupus nephritis, although the on the course of nephritis before the onset of ESRD or
the course of systemic lupus after the onset of ESRD,largest of these studies included only 97 patients with
ESRD caused by lupus nephritis [5, 16, 18, 25, 29]. Our so this study was unable to investigate these aspects of
patient outcomes.results confirm these findings in a larger sample.
Because outcomes may differ between first and subse- This study indicates that graft and patient survival
after first cadaveric and first living-related transplanta-quent transplants and between cadaveric and living-
related transplants, it is important to study these groups tion are similar in patients with ESRD caused by lupus
nephritis and those with ESRD due to other causes.separately. In comparative studies such as this, it is also
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